Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H13N3O4S |
Molecular Weight | 331.346 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CC=C3)S1(=O)=O
InChI
InChIKey=QYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
Molecular Formula | C15H13N3O4S |
Molecular Weight | 331.346 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00554Curator's Comment: Description was created based on several sources, including
https://www.pfizermedicalinformation.com/en-us/feldene
Sources: http://www.drugbank.ca/drugs/DB00554
Curator's Comment: Description was created based on several sources, including
https://www.pfizermedicalinformation.com/en-us/feldene
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P04040 Gene ID: 847.0 Gene Symbol: CAT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16789438 |
0.414 mM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10381057 |
4.4 µM [IC50] | ||
Target ID: Aminopeptidase activity Sources: https://www.ncbi.nlm.nih.gov/pubmed/26930569 |
70.0 µM [IC50] | ||
Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25522350 |
73.8 µM [IC50] | ||
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12511226 |
7.0 µM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10381057 |
1.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FELDENE Approved UseFELDENE is a nonsteroidal anti-inflammatory drug indicated for
Relief of the signs and symptoms of osteoarthritis (OA)
Relief of the signs and symptoms of rheumatoid arthritis (RA) Launch Date3.86812805E11 |
|||
Primary | FELDENE Approved UseFELDENE is a nonsteroidal anti-inflammatory drug indicated for
Relief of the signs and symptoms of osteoarthritis (OA)
Relief of the signs and symptoms of rheumatoid arthritis (RA) Launch Date3.86812805E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
135.8 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Disc. AE: Chest pain, Rash... AEs leading to discontinuation/dose reduction: Chest pain (0.74%) Sources: Page: p.260Rash (0.74%) Vomiting (0.74%) Exanthema (0.74%) Injection site pain (0.74%) |
1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea Sources: Abdominal pain Gastric ulcer Duodenal ulcer |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Disc. AE: Gastrointestinal disorders, Haemorrhage of digestive tract... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (2.6%) Sources: Page: p.158Haemorrhage of digestive tract (0.85%) Headache (0.85%) Oedema (0.85%) Pruritus (0.85%) Erythema facial (0.85%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Disc. AE: Epigastric discomfort, Diarrhoea... AEs leading to discontinuation/dose reduction: Epigastric discomfort (2.5%) Sources: Page: p.233Diarrhoea (2.5%) Loose stools (2.5%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (grade 3-5) Sources: Page: p.1Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (serious) Ulceration (serious) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Chest pain | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Exanthema | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Injection site pain | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Rash | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Vomiting | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Abdominal pain | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Duodenal ulcer | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Gastric ulcer | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Nausea | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Erythema facial | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Haemorrhage of digestive tract | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Headache | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Oedema | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Pruritus | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Gastrointestinal disorders | 2.6% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Diarrhoea | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Epigastric discomfort | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Loose stools | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Cardiac thrombosis | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Myocardial infarction | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Perforation of intestine | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Perforation stomach | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Stroke | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Bleeding | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Gastrointestinal disorder NOS | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Ulceration | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Ki 20.5 uM] | ||||
yes [Ki 23 uM] | ||||
yes [Ki 4.88 uM] | ||||
yes [Ki 70.3 uM] | ||||
yes [Ki 84.9 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (pharmacogenomic study) Comment: Higher systemic exposure of piroxicam has been noted in subjects with CYP2C9 polymorphisms compared to normal metabolizer type subject |
|||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. | 1986 Jan |
|
Piroxicam in acute musculoskeletal disorders and sport injuries. | 1987 |
|
[Fatal autoimmune hemolytic anemia probably induced by treatment with piroxicam]. | 1988 Mar 7 |
|
Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs. | 1994 Dec |
|
Comparison of ketorolac tromethamine with other injectable nonsteroidal anti-inflammatory drugs for pain-on-injection and muscle damage in the rat. | 1994 Feb |
|
Mechanism of anti-inflammatory action of fepradinol. | 1994 Jan |
|
Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. | 1999 Apr |
|
Recurrent aseptic meningitis following non- steroidal anti-inflammatory drugs--a reminder. | 1999 Dec |
|
Transport of ochratoxin A by renal multispecific organic anion transporter 1. | 1999 Jun |
|
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. | 1999 May |
|
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. | 1999 May 7 |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study. | 2002 Mar 1 |
|
Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. | 2002 Nov |
|
Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. | 2002 Sep |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. | 2003 Nov 14 |
|
Piroxicam gel, compared to EMLA cream is associated with less pain after venous cannulation in volunteers. | 2003 Oct |
|
Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. | 2004 Jul 15 |
|
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam. | 2004 Jun |
|
Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. | 2005 Jul 1 |
|
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. | 2005 Jul 14 |
|
Chemoprevention: mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker. | 2005 Mar |
|
The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. | 2005 Sep |
|
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. | 2007 Aug |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
Effect of acetaminophen, a cyclooxygenase inhibitor, on Morris water maze task performance in mice. | 2007 Sep |
|
The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells. | 2009 Apr |
|
Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS). | 2009 Jun |
|
Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. | 2010 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/piroxicam.html
Recommended dose: 20 mg orally once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11728432
Contractions induced by bradykinin in guinea-pig gallbladder smooth muscle strips were significantly attenuated by the cyclooxygenase inhibitor piroxicam (10 muM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:19:56 UTC 2022
by
admin
on
Fri Dec 16 18:19:56 UTC 2022
|
Record UNII |
13T4O6VMAM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AC01
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
WHO-VATC |
QS01BC06
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
WHO-ATC |
S01BC06
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
NCI_THESAURUS |
C1915
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
WHO-ATC |
M01AC01
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
WHO-ATC |
M02AA07
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
WHO-VATC |
QM02AA07
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
||
|
LIVERTOX |
NBK548425
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2210
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
DB00554
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
8249
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
13T4O6VMAM
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
8356
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
M8889
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | Merck Index | ||
|
DTXSID5021170
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
1544508
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
36322-90-4
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
7273
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
252-974-3
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
666076
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
54676228
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
68115
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
ALTERNATIVE | |||
|
SUB127114
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
Piroxicam
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
SUB09936MIG
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
PIROXICAM
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
3713
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
CHEMBL527
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
C751
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
D010894
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY | |||
|
13T4O6VMAM
Created by
admin on Fri Dec 16 18:19:56 UTC 2022 , Edited by admin on Fri Dec 16 18:19:56 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||